|
1
|
Kelly G: A review of the sirtuin system,
its clinical implications, and the potential role of dietary
activators like resveratrol: part 1. Altern Med Rev. 15:245–263.
2010.PubMed/NCBI
|
|
2
|
Kelly GS: A review of the sirtuin system,
its clinical implications, and the potential role of dietary
activators like resveratrol: part 2. Altern Med Rev. 15:313–328.
2010.PubMed/NCBI
|
|
3
|
Barber MF, Michishita-Kioi E, Xi Y,
Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL,
Chen K, et al: SIRT7 links H3K18 deacetylation to maintenance of
oncogenic transformation. Nature. 487:114–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang HL, Lu RQ, Xie SH, Zheng H, Wen XM,
Gao X and Guo L: SIRT7 Exhibits oncogenic potential in human
ovarian cancer cells. Asian Pac J Cancer Prev. 16:3573–3577. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu
S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and
inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep.
5:97872015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geng Q, Peng H, Chen F, Luo R and Li R:
High expression of Sirt7 served as a predictor of adverse outcome
in breast cancer. Int J Clin Exp Pathol. 8:1938–1945.
2015.PubMed/NCBI
|
|
7
|
Singh S, Kumar PU, Thakur S, Kiran S, Sen
B, Sharma S, Rao VV, Poongothai AR and Ramakrishna G:
Expression/localization patterns of sirtuins (SIRT1, SIRT2, and
SIRT7) during progression of cervical cancer and effects of sirtuin
inhibitors on growth of cervical cancer cells. Tumour Biol.
36:6159–6171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrarotto R, Pathak P, Maru D, Agarwal A,
Overman M, Hoff PM and Kopetz S: Durable complete responses in
metastatic colorectal cancer treated with chemotherapy alone. Clin
Colorectal Cancer. 10:178–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kraus S, Nabiochtchikov I, Shapira S and
Arber N: Recent advances in personalized colorectal cancer
research. Cancer Lett. 347:15–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park IJ and Yu CS: Current issues in
locally advanced colorectal cancer treated by preoperative
chemoradiotherapy. World J Gastroenterol. 20:2023–2029. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andre N and Schmiegel W: Chemoradiotherapy
for colorectal cancer. Gut. 54:1194–1202. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
Cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hajra KM, Chen DY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|
|
17
|
Deng S, Zhu S, Wang B, Li X, Liu Y, Qin Q,
Gong Q, Niu Y, Xiang C, Chen J, et al: Chronic pancreatitis and
pancreatic cancer demonstrate active epithelial-mesenchymal
transition profile, regulated by miR-217-SIRT1 pathway. Cancer
Lett. 355:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byles V, Zhu L, Lovaas JD, Chmilewski LK,
Wang J, Faller DV and Dai Y: SIRT1 induces EMT by cooperating with
EMT transcription factors and enhances prostate cancer cell
migration and metastasis. Oncogene. 31:4619–4629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ellis L, Atadja PW and Johnstone RW:
Epigenetics in cancer: Targeting chromatin modifications. Mol
Cancer Ther. 8:1409–1420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ashraf N, Zino S, Macintyre A, Kingsmore
D, Payne AP, George WD and Shiels PG: Altered sirtuin expression is
associated with node-positive breast cancer. Br J Cancer.
95:1056–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Ren X, Cheng Y, Huber-Keener K,
Liu X, Zhang Y, Yuan YS, Yang JW, Liu CG and Yang JM:
Identification of Sirtuin 3, a mitochondrial protein deacetylase,
as a new contributor to tamoxifen resistance in breast cancer
cells. Biochem Pharmacol. 86:726–733. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong XC: Sirtuin biology and relevance to
diabetes treatment. Diabetes Manag (Lond). 2:243–257. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calabrese V, Cornelius C, Leso V,
Trovato-Salinaro A, Ventimiglia B, Cavallaro M, Scuto M, Rizza S,
Zanoli L, Neri S and Castellino P: Oxidative stress, glutathione
status, sirtuin and cellular stress response in type 2 diabetes.
Biochim Biophys Acta. 1822:729–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen X, Sun K, Jiao S, Cai N, Zhao X, Zou
H, Xie Y, Wang Z, Zhong M and Wei L: High levels of SIRT1
expression enhance tumorigenesis and associate with a poor
prognosis of colorectal carcinoma patients. Sci Rep. 4:74812014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv L, Shen Z, Zhang J, Zhang H, Dong J,
Yan Y, Liu F, Jiang K, Ye Y and Wang S: Clinicopathological
significance of SIRT1 expression in colorectal adenocarcinoma. Med
Oncol. 31:9652014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng F, Su L, Yao C, Liu L, Shen J, Liu
C, Chen X, Luo Y, Jiang L, Shan J, et al: SIRT1 promotes
epithelial-mesenchymal transition and metastasis in colorectal
cancer by regulating Fra-1 expression. Cancer Lett. 375:274–283.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim S, Ahn SH, Yang HY, Lee JS, Choi HG,
Park YK and Lee TH: Modification of cysteine 457 in plakoglobin
modulates the proliferation and migration of colorectal cancer
cells by altering binding to E-cadherin/catenins. Redox Rep.
22:272–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji M, Fan D, Yuan L, Zhang Y, Dong W and
Peng X: EBP50 inhibits pancreatic cancer cell growth and invasion
by targeting the beta-catenin/E-cadherin pathway. Exp Ther Med.
10:1311–1316. 2015. View Article : Google Scholar : PubMed/NCBI
|
